Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study to assess the PK, safety and tolerability of XNW4107,
imipenem and cilastatin administered by 60-minute (60-min) IV infusion to adults with various
degrees of renal insufficiency as compared to subjects with normal renal function.